Compare MAR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAR | MRNA |
|---|---|---|
| Founded | 1927 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.5B | 91.2B |
| IPO Year | 2005 | 2018 |
| Metric | MAR | MRNA |
|---|---|---|
| Price | $414.78 | $200.83 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 29 | 23 |
| Target Price | ★ $421.73 | $164.53 |
| AVG Volume (30 Days) | 1.4M | ★ 11.4M |
| Earning Date | 11-02-2026 | 11-06-2026 |
| Dividend Yield | ★ 0.69% | N/A |
| EPS Growth | 14.17 | ★ 21.77 |
| EPS | ★ 8.36 | N/A |
| Revenue | ★ $26,186,000,000.00 | $19,263,000,000.00 |
| Revenue This Year | $6.81 | $24.09 |
| Revenue Next Year | $5.97 | $11.33 |
| P/E Ratio | $50.87 | ★ N/A |
| Revenue Growth | ★ 4.33 | 4.29 |
| 52 Week Low | $282.03 | $22.28 |
| 52 Week High | $433.30 | $280.80 |
| Indicator | MAR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.71 | 43.06 |
| Support Level | $362.04 | $181.02 |
| Resistance Level | $432.62 | $254.48 |
| Average True Range (ATR) | 10.53 | 17.92 |
| MACD | -1.75 | -7.14 |
| Stochastic Oscillator | 34.24 | 11.39 |
Marriott operates 1.8 million rooms across more than 30 brands. At the end of 2025, luxury represented roughly 10% of total rooms, premium was 42%, select service was 46%, and midscale was 2%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 99% of total rooms as of Dec. 31, 2025. North America makes up 61% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.